Safety and Efficacy Study in Subjects With Chronic HCV and Underlying Hemophilia

Not Recruiting

Trial ID: NCT01741545


The primary objective for this study is to evaluate the proportion of subjects who achieve SVR12 (HCV RNA < LLOQ (target not detected) at post-treatment follow-up Week 12 in subjects with Genotype(GT)-1b, -4 and GT-2, -3

Official Title

A Phase 3 Study Evaluating the Safety and Efficacy of Lambda/Ribavirin/Daclatasvir in Subjects With Chronic HCV Infection and Underlying Hemophilia Who Are Treatment Naïve or Are Prior Relapsers to Peginterferon Alfa-2a/Ribavirin

Stanford Investigator(s)

Mindie H. Nguyen, MD, MAS, AGAF, FAASLD
Mindie H. Nguyen, MD, MAS, AGAF, FAASLD

Professor of Medicine (Gastroenterology and Hepatology) and, by courtesy, of Epidemiology and Population Health


For more information regarding BMS clinical trial participation, please visit

Inclusion Criteria:

   - Severe hemophilia (defined as < 1% factor activity level)

   - Infection with the hepatitis C virus (HCV) with underlying hemophilia

   - Males 18 years of age and above

   - Have not been previously treated with an interferon

Exclusion Criteria:

   - Not infected with the hepatitis B virus (HBV) or human immunodeficiency virus (HIV)

   - Chronic liver disease caused by any disease other than chronic HCV infection

   - Presence of Bethesda inhibitor

   - Current evidence of or history of portal hypertension


biological: Pegylated-Interferon-lambda

drug: Ribavirin

drug: Daclatasvir

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Mindie H. Nguyen, MD